Pfizer's SBLA For 20vPnC Vaccine In Infants And Children Accepted By FDA For Priority Review

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration accepted for priority review a supplemental Biologics License Application or sBLA for its

Related Keywords

,Pfizer ,Pfizer Inc ,European Union ,European Medicines Agency ,Drug Administration ,More Such Health News ,Biologics License Application ,Prescription Drug User Fee Act ,Pnc Fast Track Designation ,Breakthrough Therapy Designation ,European Medicines ,Conjugate Vaccine ,Bla ,20vpnc ,Vaccine ,Infants ,Children ,Accepted ,Priority ,Review ,